Business Wire

Highly positive FM71 Phase 3 study results with all primary and secondary endpoints achieved, MED3000 remains on track to submit for FDA marketing authorization

GUILDFORD, England--(BUSINESS WIRE)--Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery ...
Yahoo Finanzas

US FDA Grants for Over-the-Counter Marketing Authorization to Futura for Fast-Acting Topical Gel, MED3000, to Treat Erectile Dysfunction

- Company also announced that it raised proceeds of £4,375,000 to fund future commercialization of MED3000 via a warrant exercise by a large institutional shareholder - GUILDFORD, England, June 12, ...
London South East

Futura Medical Regulatory News

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, is pleased to provide an update on good progress with its ...
Healio

Topical gel for erectile dysfunction shows promise in phase 3 trial

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In a confirmatory study, MED3000 was associated with ...
Smart Business Magazine

Smooth operators

While the Pittsburgh region might be a straggler when it comes to the state-of-the-art in medical practice management, it hasn’t hindered MED3000 from becoming a premier player in the field. When ...